<DOC>
	<DOC>NCT02807974</DOC>
	<brief_summary>To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.</brief_summary>
	<brief_title>Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male and female subjects aged 20 to 80 years at informed consent Subjects with type 2 diabetes and albuminuria (urine albumintocreatinine ratio ≥ 30, &lt; 1000 mg/g/Cr) Subjects with hypertension (Sitting SBP ≥ 140 mmHg, &lt;180 mmHg and Sitting DBP ≥ 80 mmHg, &lt;110 mmHg Treatment with an ARB or ACE inhibitor eGFR ≥ 30 mL/min/1.73m^2 Secondary hypertension or malignant hypertension Type 1 diabetes Secondary glucose intolerance Diagnosed with nondiabetic nephropathy Serum potassium level &lt; 3.5 or ≥ 4.8 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension with Type 2 Diabetes and Albuminuria</keyword>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Diabetic renal disease</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
</DOC>